Voloridge Investment Management LLC Purchases 22,291 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Share on StockTwits

Voloridge Investment Management LLC raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 1,076.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,361 shares of the biotechnology company’s stock after buying an additional 22,291 shares during the period. Voloridge Investment Management LLC’s holdings in Ascendis Pharma A/S were worth $2,346,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Ascendis Pharma A/S by 53.7% in the second quarter. Price T Rowe Associates Inc. MD now owns 7,178,036 shares of the biotechnology company’s stock worth $826,551,000 after purchasing an additional 2,509,034 shares during the last quarter. Vivo Capital LLC grew its stake in Ascendis Pharma A/S by 0.6% in the 2nd quarter. Vivo Capital LLC now owns 2,060,135 shares of the biotechnology company’s stock worth $237,225,000 after acquiring an additional 13,303 shares in the last quarter. Farallon Capital Management LLC increased its position in shares of Ascendis Pharma A/S by 2.7% during the second quarter. Farallon Capital Management LLC now owns 1,540,000 shares of the biotechnology company’s stock worth $177,331,000 after acquiring an additional 40,000 shares during the period. Sofinnova Investments Inc. increased its position in shares of Ascendis Pharma A/S by 10.1% during the second quarter. Sofinnova Investments Inc. now owns 1,099,824 shares of the biotechnology company’s stock worth $126,645,000 after acquiring an additional 101,286 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Ascendis Pharma A/S by 1,024.8% during the second quarter. Invesco Ltd. now owns 1,014,346 shares of the biotechnology company’s stock valued at $116,802,000 after acquiring an additional 924,169 shares in the last quarter.

A number of analysts recently issued reports on ASND shares. Leerink Swann reiterated an “outperform” rating and issued a $152.00 price target (up previously from $140.00) on shares of Ascendis Pharma A/S in a report on Tuesday. BidaskClub downgraded Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a report on Thursday, September 12th. Wedbush reaffirmed a “buy” rating and set a $186.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, November 19th. Morgan Stanley assumed coverage on Ascendis Pharma A/S in a research report on Friday, October 11th. They set an “overweight” rating and a $128.00 target price for the company. Finally, ValuEngine cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $150.50.

Ascendis Pharma A/S stock opened at $113.75 on Wednesday. The business has a fifty day moving average of $109.71 and a two-hundred day moving average of $112.61. The company has a quick ratio of 15.75, a current ratio of 15.74 and a debt-to-equity ratio of 0.05. The firm has a market cap of $4.85 billion, a P/E ratio of -30.41 and a beta of 0.63. Ascendis Pharma A/S has a twelve month low of $54.67 and a twelve month high of $133.96.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Further Reading: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.